An Open-label, Single-arm Clinical Study to Evaluate the Safety and Preliminary Efficacy of OriV508 Injection in Treating Relapsed/Refractory Hematological Malignancies

Must have received: anti-CD20 monoclonal antibody

Previous treatments must include standard treatment regimens with anti-CD20 monoclonal antibodies (except for subjects with CD20-negative tumors)

Must have received: anthracycline

Previous treatments must include standard treatment regimens with...anthracyclines

Cannot have received: autologous hematopoietic stem cell transplantation

Received autologous hematopoietic stem cell transplantation within 24 weeks prior to signing the ICF

Cannot have received: allogeneic hematopoietic stem cell transplantation

Received organ transplantation or allogeneic hematopoietic stem cell transplantation

Cannot have received: small molecule targeted therapy

Small molecule targeted therapy...within 14 days or at least 5 half-lives, whichever is longer

Cannot have received: epigenetic therapy

epigenetic therapy...within 14 days or at least 5 half-lives, whichever is longer

Cannot have received: investigational drug

treatment with an investigational drug or used an invasive investigational medical device within 14 days or at least 5 half-lives, whichever is longer

Cannot have received: immunosuppressive agent (tacrolimus, mycophenolate mofetil)

Immunosuppressive agent therapy (such as tacrolimus, mycophenolate mofetil, etc.) within 28 days

Cannot have received: monoclonal antibody

Monoclonal antibody treatment within 21 days

Cannot have received: cytotoxic chemotherapy

Cytotoxic therapy within 14 days

Cannot have received: proteasome inhibitor

Proteasome inhibitor therapy within 14 days

Cannot have received: immunomodulator

Immunomodulator agent therapy within 7 days

Cannot have received: corticosteroid (prednisone)

Exception: physiological replacement dose, topical and inhaled corticosteroids are permitted

Therapeutic dose of corticosteroids (defined as prednisone ≥ 20 mg/day or equivalent dose of other corticosteroids) within 72 hours

Cannot have received: radiation therapy

Exception: only for subjects whose radiation field covers > 5% of bone marrow reserve

Radiotherapy within 28 days (only for subjects whose radiation field covers > 5% of bone marrow reserve)

Cannot have received: viral therapy using vesicular stomatitis virus G (VSVG)-pseudotyped virus

Previously treated with any viral therapy using vesicular stomatitis virus G (VSVG)-pseudotyped virus